Buffalo, NY 的 非小細胞肺癌 臨床試驗
19 項針對 非小細胞肺癌 的研究正在 Buffalo（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Roswell Park Cancer Institute, Buffalo
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Roswell Park Cancer Institute, Buffalo
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Roswell Park Cancer Institute ( Site 0184), Buffalo
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- Roswell Park Cancer Institute IDS, Buffalo
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Roswell Park Cancer Institute, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Buffalo
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- Roswell Park Comprehensive Cancer Center, Buffalo
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
招募中2 期
- Research Site, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Buffalo
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- Roswell Park Cancer Institute, Buffalo
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- Roswell Park Comprehensive Cancer Center, Buffalo
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
招募中2 期
- Roswell Park Cancer Institute, Buffalo
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
招募中1 期
- Roswell Park Comprehensive Care Center, Buffalo
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
招募中1 期
- Roswell Park Cancer Institute, Buffalo
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
招募中1 期
- Roswell Cancer Institute, Buffalo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Buffalo
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
招募中
- Roswell Park Cancer Institute, Buffalo
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
招募中1/2 期
- Roswell Park Cancer Institute, Buffalo
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Buffalo 的其他研究
- 癌症（所有類型）19 項研究
- 急性髓系白血病19 項研究
- 肺癌16 項研究
- 乳癌16 項研究
- 卵巢癌13 項研究
- 轉移性癌症11 項研究
- 前列腺癌11 項研究
- 黑色素瘤10 項研究
- 多發性骨髓瘤10 項研究
- 肥胖症9 項研究
- 伯基特淋巴瘤8 項研究
- 骨髓增生異常症候群8 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。